Stockscreener 앱 받기
0.7285
1.19%
0.0086
전일 마감가:
$0.7199
열려 있는:
$0.71
하루 거래량:
55,882
Relative Volume:
0.36
시가총액:
$26.30M
수익:
-
순이익/손실:
$-10.21M
주가수익비율:
-1.247
EPS:
-0.5842
순현금흐름:
-
1주 성능:
+2.90%
1개월 성능:
-0.38%
6개월 성능:
-31.92%
1년 성능:
-65.47%
1일 변동 폭
$0.71
$0.73
1주일 범위
$0.675
$0.73
52주 변동 폭
$0.63
$2.14
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Compare NRSN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.7285 | 26.30M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - PR Newswire
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Revision Upgrade - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NRSN Forecast — Price Target — Prediction for 2027 - TradingView
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD - GuruFocus
Price to book forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s - Stock Titan
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PR Newswire
Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to EBIT forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EverythingALS to Host NeuroSense in a Community Event Named: PrimeCConnecting the Dots - The AI Journal
EverythingALS to Host NeuroSense in a Community Event Named: Pri - GuruFocus
NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NeuroSense (NRSN) CFO acquires 250,000 shares in private placement - Stock Titan
Neurosense Therapeutics Ltd (NRSN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeuroSense (NRSN) CEO acquires 250,000 shares in private placement - Stock Titan
Neurosense Therapeutics Ltd (NRSN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSN) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neurosense Therapeutics Ltd 주식 (NRSN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
2.64%
자본화:
|
볼륨(24시간):